Benjamin Hartley

Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A <i>Post Hoc</i> Cohort Analysis from the SUMMIT Randomized Clinical Trial

Ken M. Kunisaki, Mark T. Dransfield, Julie A. Anderson et al. · American Journal of Respiratory and Critical Care Medicine · 2018 · 335 citations · Full text

Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial

Steven Pascoe, Neil Barnes, Guy Brusselle et al. · The Lancet Respiratory Medicine · 2019 · 225 citations · Full text

Allergy, Advanced Lung Disease, Blood Eosinophils +5

Blood Eosinophil Count Is a Useful Biomarker to Identify Patients with Severe Eosinophilic Asthma

Lynn E. Katz, Gerald J. Gleich, Benjamin Hartley et al. · Annals of the American Thoracic Society · 2014 · 194 citations

Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial

Henrik Watz, Helen Barnacle, Benjamin Hartley et al. · The Lancet Respiratory Medicine · 2013 · 92 citations

Oncology, Pulmonary Care, Advanced Lung Disease +6

Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial

Mark T. Dransfield, Gerard J. Criner, David Halpin et al. · Journal of the American Heart Association · 2022 · 73 citations · Full text